vibostolimab

News

End of the line for MSD's TIGIT, LAG-3 cancer drugs

MSD has stopped development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline.

News

Person with their hand covering their face

More bad news for TIGIT as MSD stops another trial

Another TIGIT trial failure has been abandoned, casting a shadow once again over the target as a cancer immunotherapy strategy.

News

MSD has another TIGIT programme setback

A phase 3 trial of MSD’s anti-TIGIT antibody vibostolimab and PD-1 inhibitor pembrolizumab has been abandoned after a high rate of discontinuations rendered the study futi

End of the line for MSD's TIGIT, LAG-3 cancer drugs

More bad news for TIGIT as MSD stops another trial

MSD has another TIGIT programme setback

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

Editor's Picks